Celldex Therapeutics, Inc. (CLDX)
34.63
-3.26
(-8.60%)
USD |
NASDAQ |
Sep 22, 15:23
Celldex Therapeutics Price to Book Value : 3.804 for Sept. 22, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 21, 2026 | 4.162 |
| September 18, 2026 | 4.201 |
| September 17, 2026 | 4.282 |
| September 16, 2026 | 4.253 |
| September 15, 2026 | 4.231 |
| September 14, 2026 | 4.304 |
| September 11, 2026 | 4.054 |
| September 10, 2026 | 4.186 |
| September 09, 2026 | 4.260 |
| September 08, 2026 | 4.298 |
| September 04, 2026 | 4.359 |
| September 03, 2026 | 4.325 |
| September 02, 2026 | 4.337 |
| September 01, 2026 | 4.311 |
| August 31, 2026 | 4.354 |
| August 28, 2026 | 4.298 |
| August 27, 2026 | 4.445 |
| August 26, 2026 | 4.457 |
| August 25, 2026 | 4.528 |
| August 24, 2026 | 4.457 |
| August 21, 2026 | 4.436 |
| August 20, 2026 | 4.388 |
| August 19, 2026 | 4.581 |
| August 18, 2026 | 4.591 |
| August 17, 2026 | 4.605 |
| Date | Value |
|---|---|
| August 14, 2026 | 4.608 |
| August 13, 2026 | 4.681 |
| August 12, 2026 | 4.929 |
| August 11, 2026 | 4.87 |
| August 10, 2026 | 4.721 |
| August 07, 2026 | 4.582 |
| August 06, 2026 | 4.566 |
| August 05, 2026 | 4.511 |
| August 04, 2026 | 4.290 |
| August 03, 2026 | 4.140 |
| July 31, 2026 | 4.181 |
| July 30, 2026 | 4.228 |
| July 29, 2026 | 4.121 |
| July 28, 2026 | 3.909 |
| July 27, 2026 | 3.916 |
| July 24, 2026 | 3.876 |
| July 23, 2026 | 3.891 |
| July 22, 2026 | 3.820 |
| July 21, 2026 | 3.918 |
| July 20, 2026 | 3.891 |
| July 17, 2026 | 3.884 |
| July 16, 2026 | 3.889 |
| July 15, 2026 | 4.209 |
| July 14, 2026 | 4.193 |
| July 13, 2026 | 4.233 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Gilead Sciences, Inc. | 16.02 |
| ACADIA Pharmaceuticals, Inc. | 3.508 |
| Alnylam Pharmaceuticals, Inc. | 25.12 |
| Anika Therapeutics, Inc. | 2.021 |
| Savara, Inc. | 7.621 |
Price to Book Value Related Metrics
| PS Ratio | 15195.28 |
| PEG Ratio | -0.1769 |
| Price | 34.63 |
| Earnings Yield | -12.59% |
| Market Cap | 2.718B |
| PEGY Ratio | -0.1769 |